The Nine Lives of Hydroxychloroquine
The hydroxychloroquine story begins in 1638 when the wife of the Viceroy of Peru, Countess Cinchona, acquired malaria while living in the New World.
Blogs
Hot Stuff Part IV: Cardiovascular Outcomes and Vasculitis
The last in a four-part series from the CCF's Biologic Therapies Summit, we examine how to reduce CV risks in practice plus the current status of vasulitis management and the role biologics may play.
Hot Stuff Part III: Zoster and Biologics: Special Considerations
Part III covers talks on H. Zoster, biologics and SpA.
Top 5 Things Rheumatologists Should Know about Vaccines
Rheumatologists should have a working knowledge on what vaccinations their patients need. The top 5 things rheumatologists should know about vaccines are...
Hot Stuff Part II: Current Status and Recommendations on Vaccines and Biologics
Part II highlights from the Cleveland Clinic's Biologic Therapies Summit.
The Electronic Medical Record: the Good, the Bad and the Ugly
Many of us in academic centers, for better and worse, have had more and longer experience with EMRs than some of our colleagues in practice.
Hot Stuff from the Cleveland Clinic Biologic Therapies Summit – Part I
Highlights and take-home messages from the Cleveland Clinic Center for Continuing Education's Biologic Therapies Summit held this week (April 30 – May 2, 2015).
Does the FRAX Assessment Tool Help?
While the FRAX is useful to determine if individuals with low bone mass may benefit from treatment for osteoporosis, this method also has some shortcomings.
Knee Replacement and the Physical Terrorist
Experience is a great teacher. My experience with knee replacement surgery has taught me the integral importance of the physical therapist in individual outcomes.
Ten Pregnancy Takeaways from the ACR Reproductive Health Summit
In January 2014 the ACR convened a "Reproductive Health Summit" in Washington, DC to examine our understanding and knowledge of Pregnancy and Lactation issues in women with Rheumatic diseases. Key Stakeholders from the FDA, NIH, Womens advocacy groups, Dermatology, Gastrenterology, ACR and Pharma were asked to discuss what is know and what our unmet needs are.
